Stay updated on HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Sign up to get notified when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.

Latest updates to the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page
- Check5 days agoChange DetectedVersion updated from v3.4.2 to v3.4.3. No user-facing content or study details appear to be changed.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.2 is now shown; the prior funding-related notice and the v3.4.1 revision have been removed, with no impact on study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedIntroduced a government funding update notice and updated the site revision to v3.4.1.SummaryDifference0.4%

- Check48 days agoChange DetectedGlossary display added and metadata labels updated, including a new 'Last Update Submitted that Met QC Criteria', a 'No FEAR Act Data' notice, and a new revision tag 'Revision: v3.4.0' that supersedes the previous QC label, FEAR data note, and version v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded a Location entry for Gauteng, South Africa under Locations and updated the page revision from v3.3.2 to v3.3.3. The Gauteng Locations listing and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.2%

Stay in the know with updates to HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.